Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 11, 2007, Pages 1415-1428

  Corona, Juan C ^a   Tovar y Romo, Luis B ^a   Tapia, Ricardo ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

amino 3 hydroxy 5 isoxazole propionate receptor; Calcium; Excitotoxicity; Neurodegeneration; Spinal cord

Indexed keywords

ACETYLCYSTEINE; AEOL 10150; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA TOCOPHEROL; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; CANNABINOID RECEPTOR AGONIST; CEFTRIAXONE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; KAINIC ACID RECEPTOR; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID; NEUROTROPHIC FACTOR; PORPHYRIN; PYRUVIC ACID; RILUZOLE; SOMATOMEDIN C; TALAMPANEL; TOPIRAMATE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VESICULAR GLUTAMATE TRANSPORTER 1;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN PERFUSION; CALCIUM TRANSPORT; CELL DEATH; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENERGY METABOLISM; ENZYME INHIBITION; EPILEPSY; EXCITOTOXICITY; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MUSCLE STRENGTH; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RNA EDITING; RNA INTERFERENCE; RNA TRANSCRIPTION; SEQUENCE HOMOLOGY; SIDE EFFECT; SPINAL CORD NERVE CELL; UNSPECIFIED SIDE EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CALCIUM; CELL DEATH; CYTOPLASM; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; NEURONS; RECEPTORS, AMPA;

EID: 36749049874     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.11.1415     Document Type: Review

References (148)

1. ROSEN DR, SIDDIQUE T, PATTERSON D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59-62.
2. CHANCELLOR AM, WARLOW CP: Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J. Neurol. Neurosurg. Psychiatry (1992) 55:1106-1115.
3. ARUNDINE M, TYMIANSKI M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium (2003) 34:325-337.
4. LIPTON SA, ROSENBERG PA. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. (1994) 330:613-622.
5. TAPIA R, MEDINA-CEJA L, PEÑA F: On the relationship between extracellular glutamate, hyperexcitation and neurodegeneration, in vivo. Neurochem. Int. (1999) 34:23-31.
6. MELDRUM BS: Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. (2000) 130:S1007-S1015.
7. BOILLEE S, VANDE VELDE C, CLEVELAND DW: ALS: a disease of motor neurons and their non-neuronal neighbors. Neuron (2006) 52:39-59.
8. ROWLAND LP, SHNEIDER NA. Amyotrophic lateral sclerosis. N. Engl. J. Med (2001) 344:1688-1700.
9. BRUIJN LI, MILLER TM, CLEVELAND DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. (2004) 27:723-749.
10. JULIEN JP: Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell (2001) 104:581-591.
11. SHAW PJ: Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Pychiatry (2005) 76:1046-1057.
12. HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Annu. Rev. Neurosci. (1994) 17:31-108.
13. BETTLER B, MULLE C: Review. neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology (1995) 34:123-139.
14. PIN JP, DUVOISIN R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology (1995) 34:1-26.
15. KANNER BI: Ion-coupled neurotransmitter transport. Curr. Opin. Cell Biol. (1989) 1:735-738.
16. GADEA A, LOPEZ-COLOME AM: Glial transporters for glutamate, glycine and GABA 1. Glutamate transporters. J. Neurosci. Res. (2001) 63:453-460.
17. DANBOLT NC: Glutamate uptake. Prog. Neurobiol. (2001) 65:1-105.
18. TANAKA K, WATASE K, MANABE T et al.: Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science (1997) 276:1699-1702.
19. ROTHSTEIN JD, MARTIN LJ, KUNCL RW. Decreased glucamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. (1992) 326:1464-1468.
20. ROTHSTEIN JD, VAN KAMMEN M, LEVEY AI, MARTIN LJ, KUNCL RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. (1995) 38:73-84.
21. SHAW PJ, FORREST V, INCE PG, RICHARDSON JP, WASTELL HJ: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration (1995) 4:209-216.
22. SPREUX-VAROQUAUX O, BENSIMON G, LACOMBLEZ L et al.: Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol Sci. (2002) 193:73-78.
23. CORONA JC, TAPIA R: AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo. J. Neurochem. (2004) 89:988-997.
24. TOVAR-Y-ROMO LB, TAPIA R: Cerebral neurons of transgenic ALS mice are vulnerable to glummate release stimulation but not to increased extracellular glutamate due to transport blockade. Exp. Neurol. (2006) 199:281-290.
25. AYALA GX, TAPIA R: Late N-methyl-D-asparcate receptor blockade rescues hippocampal neurons from excitotoxic stress and death after 4-aminopyridine-induced epilepsy. Eur. J. Neurosci. (2005) 22:3067-3076.
26. AYALA GX, TAPIA K: Expression of heat shock protein 70 induced by 4-aminopyridine through glutamate-mediated excitotoxic stress in rat hippocampus in vivo. Neuropharmacology (2003) 45:649-660.
27. PEÑA F, TAPIA R. Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience (2000) 101:547-561.
28. HUME RI, DINGLEDINE R, HEINEMANN SF: Identification of a site in glutamate receptor subunits that controls calcium permeability. Science (1991) 253: 1028-1031.
29. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science (1991) 252:851-853.
30. BURNASHEV N, MONYER H, SEEBURG PH, SAKMANN B: Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron (1992) 8:189-198.
31. CHOI DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 1:623-634.
32. COYLE JT, PUTTFARCKEN P: Oxidative stress, glutamate, and neurodegenerative disorders. Science (1993) 262:689-695.
33. CELIO MR: Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience (1990) 35:375-475.
34. PALECEK J, LIPS MB, KELLER BU: Calcium dynamics and buffering in motoneurones of the mouse spinal cord. J. Physiol. (1999) (520 Part 2):485-502.
35. INCE P, STOUT N, SHAW P et al.: Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. (1993) 19:291-299.
36. ALEXIANU ME, HO BK, MOHAMED AH et al.: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. (1994) 36:846-858.
37. SASAKI S, WARITA H, KOMORI T et al.: Parvalbumin and calbindin D-28k immunoreactivity in transgenic mice with a G93A mutant SOD1 gene. Brain Res. (2006) 1083:196-203.
38. SIKLÓS L, ENGELHARDT JI, ALEXIANU ME et al.: Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. J. Neuropathol. Exp. Neurol. (1998) 57:571-587.
39. 2+ transients in cultured spinal motor neurons. Cell Calcium (2007) 42:59-69.
40. JAHN K, GROSSKREUTZ J, HAASTERT K et al.: Temporospatial coupling of nerworked synaptic activation of AMPA-type glutamate receptor channels and calcium transients in cultured motoneurons. Neuroscience (2006) 142:1019-1029.
41. CARRIEDO SG, YIN HZ, WEISS JH: Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. (1996) 16:4069-4079.
42. WILLIAMS TI, DAY NC, INCE PG, KAMBQJ RK, SHAW PJ: Calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. (1997) 42:200-207.
43. 2+-permeable AMPA receptors and selective vulnerability of motor neurons. J. Neurol. Sci. (2000) 180:29-34.
44. GREIG A, DONEVAN SD, MUJTABA TJ, PARKS TN, RAO MS: Characterization of the AMPA-activated receptors present on motoneurons. J. Neurochem. (2000) 74:179-191.
45. VAN DAMME P VAN DEN BOSCH L, VAN HOUTTE E, CALLEWAERT G, ROBBERECHT W: GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J. Neurophysiol. (2002) 88:1279-1287.
46. TOMIYAMA M, RODRIGUEZ-PUERTAS R, CORTES R et al.: Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualized by in situ hybridization. Neuroscience (1996) 75:901-915.
47. VIRGO L, SAMARASINGHE S, DE BELLEROCHE J: Analysis of AMPA receptor subunit mRNA expression in control and ALS spinal cord. Neuroreport (1996) 7:2507-2511.
48. BAR-PELED O, O'BRIEN RJ, MORRISON JH, ROTHSTEIN JD: Cultured motor neurons possess calcium-pcnneable AMPA/kainate receptors. Neuroreport (1999) 10:855-859.
49. KAWAHARA Y, KWAK S, SUN H et al.: Human spinal motoneurons express low relative abundance of GluR2 mRNA. an implication for excitotoxicity in ALS. J. Neurochem. (2003) 85:680-689.
50. TAKUMA H, KWAK S, YOSHIZAWA T, KANAZAWA I: Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann. Neurol. (1999) 46:806-815.
51. KAWAHARA Y, ITO K, SUN H et al.: Glutamte receptors: RNA editing and death of motor neurons. Nature (2004) 427:801.
52. KWAK S, KAWAHARA Y: Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J. Mol. Med. (2005) 83:110-120.
53. KAWAHARA Y, SUN H, ITO K et al.: Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci. Res. (2006) 54:11-14.
54. GURNEY ME, PU H, CHIU AY et al.: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science (1994) 264:1772-1775.
55. NAGAI M, AOKI M, MIYOSHI I et al.: Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci. (2001) 21:9246-9254.
56. HOWLAND DS, LIU J, SHE Y et al.: Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA (2002) 99:1604-1609.
57. 2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci. Res. (1997) 29:27-36.
58. NOH KM, YOKOTA H, MASHIKO T et al.: Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc. Natl. Acad. Sci. USA (2005) 102:12230-12235.
59. 2+ accumulation and neuronal loss in hippocampal pyramidal neurons. J. Neurosci. (2002) 22:1273-1279.
60. 2+ determine motoneuron vulnerability in rat spinal cord in vivo. Neurophamacology (2007) 52:1219-1228.
61. TOVAR-Y-ROMO LB, ZEPEDA A, TAPIA R: Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J. Neuropathol. Exp. Neurol. (2007) 66:913-922.
62. DOBLE A: The pharmacology and mechanism of action of riluzole. Neurology (1996) 47:S233-S241.
63. LACOMBLEZ L, BENSIMON G, LEIGH PN, GUILLET P, MEININGER V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet (1996) 347:1425-1431.
64. BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N. Engl. J. Med. (1994) 330:585-591.
65. BENSIMON G, LACOMBLEZ L, DELUMEAU JC et al.: A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. (2002) 249:609-615.
66. LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2002) 3:23-29.
67. GURNEY ME, CUTTING FB, ZHAI P et al.: Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. (1996) 39:147-157.
68. + current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J. Physiol. (2005) 563:843-854.
69. SKRADSKI S, WHITE HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia (2000) 41:S45-S47.
70. MARAGAKIS NJ, JACKSON M, GANEL R, ROTHSTEIN JD: Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci. Lett. (2003) 338:107-110.
71. CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:456-464.
72. LANGAN YM, LUCAS R, JEWELL H, et al.: Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia (2003) 44:46-53.
73. ROTHSTEIN JD, PATEL S, REGAN MR et al.: β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 433:73-77.
74. PARDO AC, WONG V. BENSON LM et al.: Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1 (G93A) mice. Exp. Neurol. (2006) 201:120-130.
75. 2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. (2005) 28:494-500.
76. MANFREDI G, XU Z: Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion (2005) 5:77-87.
77. MENZIES FM, INCE PG, SHAW PJ: Mitochondrial involvement in amyotropliic lateral sclerosis. Neurochem. Int. (2002) 40:543-551.
78. SWERDLOW RH, PARKS JK, CASSARINO DS et al.: Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. (1998) 153:135-142.
79. KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. (1999) 5:347-350.
80. ZHANG W, NARAYANAN M, FRIEDLANDER RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. (2003) 53:267-270.
81. PARK JH, HONG YH, KIM HJ et al.: Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci. Lett. (2007) 413:265-269.
82. SHEFNER JM, CUDKOWICZ ME, SCHOENFELD D et al.: A clinical trial of creatine in ALS. Neurology (2004) 63:1656-1661.
83. MATTHEWS RT, YANG L, BROWNE S, BAIK M, BEAL MF: Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts nettroprotective effects. Proc. Natl. Acad. Sci. USA (1998) 95:8892-8897.
84. LEVY G, KAUFMANN P BUCHSBAUM R et al.: A two-stage design for a Phase II clinical trial of coenzyme Q10 in ALS. Neurology (2006) 66:660-663.
85. FERRANTE KI, SHEFNER J, ZHANG H et al.: Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology (2005) 65:1834-1836.
86. 2+ overload and ROS generation in spinal motor neurons in vitro. J. Neurosci. (2000) 20:240-250.
87. RAO SD, YIN HZ, WEISS JH: Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J. Neurorci. (2003) 23:2627-2633.
88. ABE K, PAN LH, WATANABE M et al.: Upregulation of protein-tyrosine nitration in the anterior hom cells of amyotrophic lateral sclerosis. Neurol. Res. (1997) 19:124-128.
89. BEAL MF, FERRANTE RJ, BROWNE SE et al.: Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. (1997) 42:644-654.
90. FERRANTE RJ, BROWNE SE, SHINOBU LA et al.: Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. (1997) 69:2064-2074.
91. SHAW PJ, INCE PG, FALKOUS G, MANTLE D: Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol (1995) 38:691-695.
92. BOGDANOV M, BROWN RH, MATSON W et al.: Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. (2000) 29:652-658.
93. DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2001) 2:9-18.
94. GRAF M, ECKER D, HOROWSKI R et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J. Neural. Transm. (2005) 112:649-660.
95. LOUWERSE ES, WEVERLING GJ, BOSSUYT PM, MEYJES FE, DE JONG JM: Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch. Neurol. (1995) 52:559-564.
96. ANDREASSEN OA, DEDEOGLU A, KLIVENYI P, BEAL ME BUSH AI: N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport (2000) 11:2491-2493.
97. LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol. (1998) 55:93-96.
98. CROW JP, CALINGASAN NY, CHEN J, HILL JL, BEAL MF: Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. (2005) 58:258-265.
99. ORRELL RW: AEOL-10150 (Aeolus). Curr. Opin. Investig. Drugs (2006) 7:70-80.
100. KOTZBAUER PT, HOLTZMAN DM: Expectations and challenges in the therapeutic use of nettrotrophic factors. Ann. Neurol. (2006) 59:444 447.
101. SENDTNER M, SCHMALBRUCH H, STOCKLI KA et al.: Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature (1992) 358:502-504.
102. MITSUMOTO H, IKEDA K, HOLMLUND T et al.: The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. (1994) 36:142-148.
103. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurorrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF treatment study group. Neurology (1996) 46:1244-1249.
104. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF study group (Phase III). Neurology (1999) 52:1427-1433.
105. BORASIO GD, ROBBERECHT W, LEIGH PN et al.: A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. European ALS/IGF-1 study group. Neurology (1998) 51:583-586.
106. LAI EC, FELICE KJ, FESTOFF BW et al.: Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I study group. Neurology (1997) 49:1621-1630.
107. AZZOUZ M, RALPH GS, STORKEBAUM E et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 429:413-417.
108. KASPAR BK, LLADO J, SHERKAT N, ROTHSTEIN JD, GAGE FH: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 301:839-842.
109. WANG LJ, LU YY, MURAMATSU S et al.: Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. (2002) 22:6920-6928.
110. STORKEBAUM E, LAMBRECHTS D, DEWERCHIN M et al.: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. (2005) 8:85-92.
111. WANG Y, MAO XO, XIE L et al.: Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. (2007) 27:304-307.
112. ZHENG C, NENNESMO I, FADEEL B, HENTER JI: Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. (2004) 56:564-567.
113. OOSTHUYSE B, MOONS L, STORKEBAUM E et al.: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. (2001) 28:131-138.
114. LAMBRECHTS D, STORKEBAUM E, MORIMOTO M et al.: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. (2003) 34:383-394.
115. LI B, XU W, LUO C, GOZAL D, LIU R. VEGF-induced activation of the P13-K/ Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Mol. Brain Res. (2003) 111:155-164.
116. NEWBERN J, TAYLOR A, ROBINSON M, LI L, MILLIGAN CE: Decreases in phosphoinositide-3-kinase/Akt and extracellular signal-regulated kinase 1/2 signaling activate components of spinal motoneuron death. J. Neurochem. (2005) 94:1652-1665.
117. YU F, SUGAWARA T, MAIER CM, HSIEH LB, CHAN PH: Akt/Bad signaling and motor neuron survival after spinal cord injury. Neurobiol. Dis. (2005) 20:491-499.
118. MATSUZAKI H, TAMATANI M, YAMAGUCHI A et al.: Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J. (2001) 15:1218-1220.
119. BROWN RH Jr: Superoxide dismutase in familial amyotrophic lateral sclerosis: models for gain of function. Curr. Opin. Neurobiol. (1995) 5:841-846.
120. REAUME AG, ELLIOTT JL, HOFFMAN EK et al.: Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. (1996) 13:43-47.
121. RALPH GS, RADCLIFFE PA, DAY DM et al.: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. (2005) 11:429-433.
122. RAOUL C, ABBAS-TERKI T, BENSADOUN JC et al.: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. (2005) 11:423-428.
123. XIA X, ZHOU H, HUANG Y, XU Z: Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis. (2006) 23:578-586.
124. SCHWARZ DS, DING H, KENNINGTON L et al.: Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. (2006) 2:E140.
125. XIA XG, ZHOU H, ZHOU S et al.: An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J. Neurochem. (2005) 92:362-367.
126. URUSHITANI M, SIK A, SAKURAI T et al.: Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. (2006) 9:108-118.
127. TURNER BJ, ATKIN JD, FARG MA et al.: Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci. (2005) 25:108-117.
128. URUSHITANI M, EZZI SA, JULIEN JP: Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA (2007) 104:2495-2500.
129. HENKEL JS, ENGELHARDT JI, SIKLOS L et al.: Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. (2004) 55:221-235.
130. KAWAMATA T, AKIYAMA H, YAMADA T, MCGEER PL: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. (1992) 140:691-707.
131. TURNER MR, CAGNIN A, TURKHEIMER FE et al.: Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C] (R)-PK11195 positron emission tomography study. Neurobiol. Dis. (2004) 15:601-609.
132. HENKEL JS, BEERS DR, SIKLOS L, APPEL SH: The chemokine MCP-1 and the dendritic and mycloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell Neurosci. (2006) 31:427-437.
133. SARGSYAN SA, MONK PN, SHAW PJ: Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia (2005) 51:241-253.
134. WEST M, MHATRE M, CEBALLOS A et al.: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor a activation of microglia and extends survival of G93A-SOD1 transgenic mice. J. Neurochem. (2004) 91:133-143.
135. YRJANHEIKKI J, TIKKA T, KEINANEN R et al.: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA (1999) 96:13496-13500.
136. TIKKA TM, VARTIAINEN NE, GOLDSTEINS G et al.: Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain (2002) 125:722-731.
137. KRIZ J, NGUYEN MD, JULIEN JP: Minocychne slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurebiol. Dis. (2002) 10:268-278.
138. VAN DEN BOSCH L, TILKIN P, LEMMENS G, ROBBERECHT W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13:1067-1070.
139. ZHU S, STAVROVSKAYA IG, DROZDA M et al.: Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417:74-78.
140. SATHASIVAM S, GRIERSON AJ, SHAW PJ: Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol. Appl. Neurobiol. (2005) 31:467-485.
141. SHOEMAKER JL, SEELY KA, REED RL, CROW JP, PRATHER PL: The CB2 cannabinoid agonist AMA-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. (2007) 101:87-98.
142. LINO MM, SCHNEIDER C, CARONI P: Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. (2002) 22:4825-4832.
143. PRAMATAROVA A, LAGANIERE J, ROUSSEL J, BRISEBOIS K, ROULEAU GA: Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. (2001) 21:3369-3374.
144. GONG YH, PARSADANIAN AS, ANDREEVA A, SNIDER WD, ELLIOTT JL: Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. (2000) 20:660-665.
145. VANDENBERGHE W, VAN DEN BOSCH L, ROBBERECHT W: Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. Brain Res. (1998) 807: 1-10.
146. DI GIORGIO FP, CARRASCO MA, SIAO MC, MANIATIS T, EGGAN K: Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. (2007) 10:608-614.
147. NAGAI M, RE DB, NAGATA T et al.: Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. (2007) 10:615-622.
148. CLEMENT AM, NGUYEN MD, ROBERTS EA et al.: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 302:113-117.